Pricing Log in Create free account

Ultragenyx Pharmaceutical Inc. (RARE) vs SELLAS Life Sciences Group, Inc. (SLS)

Ultragenyx Pharmaceutical Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Ultragenyx Pharmaceutical Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($1.6B and $1.5B). SELLAS Life Sciences Group, Inc. has the higher net margin (0.00% vs −71.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, SELLAS Life Sciences Group, Inc. leads on 8 and Ultragenyx Pharmaceutical Inc. on 5.

Valuation

Metric RARE SLS Biotechnology median
P/E n/m n/m 10.60
P/S 2.17 149.37 9.40
P/B n/m 11.39 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1.80 136.22 9.02
Earnings yield (33.48%) (2.53%) (32.88%)
Free cash flow yield (28.26%) (2.45%) (23.13%)

Profitability

Metric RARE SLS Biotechnology median
Gross margin 82.88% 0.00% 68.51%
Operating margin (63.97%) 0.00% 0.00%
Net margin (71.78%) 0.00% 0.00%
Free cash flow margin (61.23%) 0.00% 0.00%
Return on equity 285.68% (39.63%) (51.96%)
Return on assets (44.08%) (36.54%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric RARE SLS Biotechnology median
Revenue growth (TTM) 15.75% — 6.76%
EPS growth (last fiscal year) 7.31% 50.00% 29.88%
Revenue growth, 5-year CAGR 19.95% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RARE SLS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.40 18.83 4.97
Net debt to EBITDA 1.35 2.54 1.01

Dividend

Metric RARE SLS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric RARE SLS Biotechnology median
Market cap 1.54b 1.59b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack